I would keep an eye on their soon to be competitor: ADMP
Their epipen is on track to be approved (June I think) and costs a fraction of Mylans epipen. They had some problems with the FDA: got 2 CRL by the FDA which imo was nothing more than BP pushing back. But they have a good chance of getting approved this time around, especially given the recent climate around Mylan.
Their epipen is on track to be approved (June I think) and costs a fraction of Mylans epipen. They had some problems with the FDA: got 2 CRL by the FDA which imo was nothing more than BP pushing back. But they have a good chance of getting approved this time around, especially given the recent climate around Mylan.
1